Madrigal Pharmaceuticals Inc (MDGL.OQ)
22 Jan 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|74||2016||Chairman of the Board, Chief Executive Officer|
|65||2016||Founder, Chief Medical Officer, Executive Vice President, Research & Development and Director|
|63||2014||Chief Financial Officer, Senior Vice President|
|70||2016||Lead Independent Director|
- BRIEF-Madrigal Pharmaceuticals Prices Public Offering Of Common Stock
- BRIEF-Madrigal Pharma Announces Proposed Public Offering Of Common Stock
- BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Biopsy-Proven Non-Alcoholic Steatohepatitis In Phase 2 Clinical Trial
- BRIEF-Madrigal Pharmaceuticals reports Q3 loss per share of $0.68
- BRIEF-Madrigal Pharmaceuticals announces outcome from pre-planned DSMB safety review and completion of enrollment of phase 2 study of MGL-3196